Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Finance Watch: Six More IPO Filings As Three More Biopharmas Go Public In The US

Executive Summary

Public Company Edition: Kiniksa, Scholar Rock and Iterum launch the most recent US IPOs and at least five more drug developers join the queue. Also, Polyphor go public in Switzerland, Valeant and Ligand sell notes, and MyoKardia led recent follow-on offerings.

Advertisement

Related Content

Deal Watch: Allergan, Celgene, AstraZeneca Among Biopharmas Advancing Existing Partnerships
Finance Watch: VC Investment Soars In Q1, Putting Biopharma On Track For A Record Year
Finance Watch: Despite Bad News, IPOs And Public Offerings Keep Flowing
PRIME Dry Spell Ends As EMA Takes On Eye Disease Gene Therapy
Finance Watch: Mysterious Gossamer Raises $100m As VC Deals Surge Ahead of J.P. Morgan
Pipeline Watch: Phase III Starts For BL-8040, Trigriluzole, MIN-101
Aptinyx Reaches Milestones, Raises $70m To Develop NMDA Modulators
IPO Update: Biopharma Firms Give Thanks For Receptive US Investors
Iterum Therapeutics Focused On First Oral Penem
MedImmune, Abpro’s Unspecific Plans For Bispecific Antibody Collaboration

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC123158

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel